GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
Rating: JAZZ
Neutral $140

JAZZ PHARMA INC (NASDAQ: JAZZ) downgraded to Neutral with price target $140 by Mizuho

Tuesday,  Nov 10, 2015  8:25 AM ET by Betsy O'Brien Harrison

Mizuho downgraded JAZZ PHARMA INC (NASDAQ: JAZZ) to Neutral with price target
$140. Previously Mizuho downgraded to JAZZ PHARMA INC (NASDAQ: JAZZ) to Buy with price target $80 on 05/09/2012, when the stock price was $48.64.

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products to meet unmet medical needs in neurology and psychiatry. The marketed products and late-stage product candidate of the Company include Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) extended-release capsules and JZP-6 (sodium oxybate). The other product candidates in clinical development are JZP-8 (intranasal clonazepam), being developed for the treatment of recurrent acute repetitive seizures in epilepsy patients who continue to have seizures while on stable anti-epileptic regimens, JZP-4 (sodium and calcium channel antagonist), being developed for the treatment of epilepsy and bipolar disorder, and JZP-7 (ropinirole gel), being developed for the treatment of restless legs syndrome.

Mizuho



RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy